This is a preview of subscription content, log in via an institution to check access.
Notes
Infectious Disease Society of America/Society for Healthcare Epidemiology of America
Infectious Disease Society of America/Society for Healthcare Epidemiology of America
Reference
Rajasingham R, et al. Cost-effectiveness of treatment regimens for Clostridioides difficile infection - an evaluation of the 2018 Infectious Diseases Society of America guidelines. Clinical Infectious Diseases : 17 Apr 2019. Available from: URL: http://doi.org/10.1093/cid/ciz318
Rights and permissions
About this article
Cite this article
Fidaxomicin good value in C. difficile infection despite cost. PharmacoEcon Outcomes News 827, 18 (2019). https://doi.org/10.1007/s40274-019-5856-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-5856-z